1. Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement
- Author
-
Alberto Ortiz Saez, Andrés Íñiguez Romo, Jose Antonio Baz Alonso, Saleta Fernández Barbeira, Emilio Galán, Sergio Raposeiras Roubin, Raúl Moreno, Eduardo Molina Navarro, Guillermo Bastos Fernández, Rafael Romaguera, Francisco Calvo Iglesias, Pablo Juan Salvadores, Ángel Cequier Fillat, Juan Ocampo Miguez, Mariano Valdes Chavarri, Antonio De Miguel Castro, Antonio Serra Peñaranda, Ignacio Cruz Gonzalez, Victor Alfonso Jimenez Diaz, and Antonio Tello-Montoliu
- Subjects
constricción patológica ,Aortic valve ,medicine.medical_specialty ,trombosis ,Terapia antitrombótica ,medicine.medical_treatment ,Estenosis aórtica ,enfermedades cardiovasculares ,Constriction, Pathologic ,macromolecular substances ,030204 cardiovascular system & hematology ,Ensaio REAC-TAVI ,03 medical and health sciences ,0302 clinical medicine ,P2Y12 ,Valve replacement ,aortic s ,Internal medicine ,medicine ,Clinical endpoint ,cardiovascular diseases ,030212 general & internal medicine ,Heart Valve Prosthesis Implantation ,implantación de prótesis valvulares cardíacas ,business.industry ,Thrombosis ,medicine.disease ,Clopidogrel ,Stenosis ,medicine.anatomical_structure ,Cardiovascular Diseases ,Aortic Valve ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,válvula aórtica ,Ticagrelor ,medicine.drug - Abstract
OBJECTIVES: The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI. BACKGROUND: Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence. METHODS: This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU
- Published
- 2019